- Ximeclav 250 tablet: Each film-coated tablet contains Cefuroxime 250 mg as Cefuroxime Axetil USP and Clavulanic Acid 62.5 mg as Clavulanate Potassium BP.
- Ximeclav 500 tablet: Each film-coated tablet contains Cefuroxime 500 mg as Cefuroxime Axetil USP and Clavulanic Acid 125 mg as Clavulanate Potassium BP.
- Ximeclav Powder for Suspension: Each 5 ml reconstituted suspension contains Cefuroxime 125 mg as Cefuroxime Axetil USP and Clavulanic Acid 31.25 mg as Clavulanate Potassium BP.
Cefuroxime is a second generation cephalosporin antibiotics which is bactericidal and active against a wide range of Gram (+) ve and Gram (-) ve susceptible organisms including many beta-lactamase producing strains. It is indicated for the treatment of infections caused by sensitive bacteria. Clavulanic acid has a similar structure to the beta-lactam antibiotics but binds irreversibly to the beta-lactamase enzymes. The presence of clavulanic acid in Ximeclav formulation protects the effectiveness of Cefuroxime from degradation by beta-lactamase enzymes and effectively extends the antibacterial spectrum of Cefuroxime to include many bacteria normally resistant to Cefuroxime and other cephalosporin. Use of Clavulanic acid in combination with the beta-lactam antibiotic becomes one of the most prescribed antibiotics prolonging the effective life of antibiotics. Thus, the combination of Cefuroxime and Clavulanic acid (beta-lactamase inhibitor) provides a solution for treatment of bacterial infections caused by beta-lactam resistant pathogens.